Nephrocare Health Services Ltd (NEPHROPLUS) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 544647 | NSE: NEPHROPLUS | Hospital & Healthcare Services |

Nephrocare Health Se Share Price

449.85 -11.95 -2.59%
as on 19-Dec'25 16:59

DeciZen - make an informed investing decision on Nephrocare Health Se

Based on:

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Nephrocare Health Services stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
135.35
Market Cap:
4,633.7 Cr.
52-wk low:
456.1
52-wk high:
498.7

Is Nephrocare Health Services Ltd an attractive stock to invest in?

1. Is Nephrocare Health Services Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Nephrocare Health Services Ltd is a below average quality company.

2. Is Nephrocare Health Services Ltd undervalued or overvalued?

The key valuation ratios of Nephrocare Health Services Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Nephrocare Health Services Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Nephrocare Health Services Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Nephrocare Health Se:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Nephrocare Health Services Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'23Mar'24Mar'25TTM
ROCE % 0.4%2.9%9.6%-
Value Creation
Index
-1.0-0.8-0.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 386436544544
Sales YoY Gr.-13%24.6%-
Adj EPS -15.64.732.43.4
YoY Gr.-NA587.1%-
BVPS (₹) 442.7451.1595.889.3
Adj Net
Profit
-15.74.933.834
Cash Flow from Ops. 11.156.879.7-
Debt/CF from Ops. 17.63.11.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANANA24.6%
Adj EPS NANANA587.1%
BVPSNANANA32.1%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'23Mar'24Mar'25TTM
Return on
Equity %
-41.27.21
Op. Profit
Mgn %
9.812.217.5NAN
Net Profit
Mgn %
-4.11.16.26.3
Debt to
Equity
0.50.50.2-
Working Cap
Days
02431780
Cash Conv.
Cycle
0103840

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 1.00%

Sales growth has been subdued in last 3 years 0.00%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Nephrocare Health Services Ltd.

Standalone Consolidated
TTM EPS (₹) 3.4 6.7
TTM Sales (₹ Cr.) 544 756
BVPS (₹.) 89.3 93.5
Reserves (₹ Cr.) 876 918
P/BV 5.17 4.94
PE 135.35 69.06
From the Market
52 Week Low / High (₹) 456.05 / 498.70
All Time Low / High (₹) 463.50 / 498.70
Market Cap (₹ Cr.) 4,634
Equity (₹ Cr.) 20.1
Face Value (₹) 2
Industry PE 87.7

Management X-Ray of Nephrocare Health Se:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Nephrocare Health Se - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Nephrocare Health Se

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Sales386436544
Operating Expenses 348384449
Manufacturing Costs103136171
Material Costs133139149
Employee Cost 857293
Other Costs 273835
Operating Profit 385295
Operating Profit Margin (%) 9.8%11.9%17.5%
Other Income 5816
Interest 151714
Depreciation 414351
Exceptional Items 000
Profit Before Tax -13045
Tax 3-411
Profit After Tax -15434
PAT Margin (%) -4.0%0.9%6.3%
Adjusted EPS (₹)-17.84.438.8
Dividend Payout Ratio (%)0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 389398529
Share Capital 555
Reserves 383393524
Minority Interest000
Debt173157106
Long Term Debt816446
Short Term Debt929360
Trade Payables144161
Others Liabilities 544842
Total Liabilities 630644739

Fixed Assets

Gross Block308397455
Accumulated Depreciation139178221
Net Fixed Assets 169219234
CWIP 314
Investments 148149212
Inventories221918
Trade Receivables129138194
Cash Equivalents 3233
Others Assets 15611743
Total Assets 630644739

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Cash Flow From Operating Activity 115780
PBT -13045
Adjustment 576461
Changes in Working Capital -37-2-30
Tax Paid 4-63
Cash Flow From Investing Activity -75-23-104
Capex -39-74-81
Net Investments -546-25
Others -3162
Cash Flow From Financing Activity 63-3626
Net Proceeds from Shares -1198
Net Proceeds from Borrowing 19-19-22
Interest Paid -15-17-14
Dividend Paid 000
Others 60-1-36
Net Cash Flow -0-12

Finance Ratio

PARTICULARSMar'23Mar'24Mar'25
Ratios
ROE (%)-4.0217.44
ROCE (%)0.362.99.56
Asset Turnover Ratio0.610.690.79
PAT to CFO Conversion(x)N/A14.252.35
Working Capital Days
Receivable Days122112111
Inventory Days211712
Payable Days4073125

Nephrocare Health Services Ltd Stock News

Nephrocare Health Services Ltd FAQs

The current trading price of Nephrocare Health Se on 19-Dec-2025 16:59 is ₹449.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-Dec-2025 the market cap of Nephrocare Health Se stood at ₹4,633.7.
The latest P/E ratio of Nephrocare Health Se as of 18-Dec-2025 is 135.3.
The latest P/B ratio of Nephrocare Health Se as of 18-Dec-2025 is 5.17.
The 52-week high of Nephrocare Health Se is ₹498.7 and the 52-week low is ₹456.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nephrocare Health Se is ₹543.6 ( Cr.) .

About Nephrocare Health Services Ltd

Nephrocare Health Services was incorporated as ‘Nephrocare Health Services Private Limited’ on December 18, 2009. Pursuant to resolutions dated April 11, 2025 and June 2, 2025 passed by its Board and Shareholders, respectively, the company was converted into a public limited company and consequently, the name of the company was changed to ‘Nephrocare Health Services Limited’ on June 18, 2025.

It offers comprehensive dialysis care through its network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy. It has a global network of over hundreds of clinics and has the most widely distributed dialysis network in India with an extensive pan-India network of clinics across hundreds of cities and many States and several Union Territories. Its widespread presence ensures patients have easy accessibility to dialysis services.

It enhances patient accessibility by operating its network of clinics across various formats including in-hospital captive clinics, standalone clinics, and government-backed public private partnerships (PPPs) - enabling it to serve patients in private hospitals and government facilities. It operates a scalable, asset-light and capital efficient business model, which helps ensure quick clinic additions and ramp-ups with low capital expenditure, as well as a high return on capital employed, economies of scale and strong unit economics.

Business area of the company

Nephrocare Health Services is engaged in offering comprehensive dialysis care through its network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy. Its widespread presence ensures patients have easy accessibility to dialysis services.

Services of the company

Dialysis Services

  • Haemodialysis
  • Peritoneal dialysis

In-Clinic Dialysis Services

  • Captive Model through Arrangements with Hospitals
  • Standalone clinics 
  • Public-Private Partnership (PPP) clinics

Off-Clinic Dialysis Services

  • Home haemodialysis (HHD)
  • Dialysis on call (DoC)
  • Dialysis on wheel (DoW)

Awards and recognitions

  • 2017: Awarded the Business Models Innovation Awards for the Best Medical Services Outsourcer at HBI Business Model Innovation Awards by Healthcare Business International in association with KPMG 
  • 2019: Awarded the Indian Dialysis Service Provider Company of the Year Award 2019 by Frost and Sullivan 
  • 2022: Awarded the Single Specialty Hospital of the Year award by the grand jury of the 12th MT India Healthcare Awards 2022 and Medgate Today magazine 
  • 2024: Awarded the “Innovation in Health” award at the 14th edition of Aegis Graham Bell Awards 
  • 2025: Received the Guinness World Records for the most people to sign-up for a kidney screening online in one week 
  • 2025: Received the India Book of Records for maximum people screened for serum creatinine test held at multiple venues 
  • 2025: Awarded the “Dialysis Chain of the Year - National” award at the Economic Times Healthcare Awards 2025

History and millstones

  • 2010: Launched its first standalone clinic in Banjara Hills, Hyderabad, India. 
  • 2012: Launched its first Public Private Partnership (PPP) clinic in Sananth Nagar, Hyderabad, India 
  • 2015: Launched 50th dialysis clinic and crossed 10,000 plus treatments per month 
  • 2018: Acquired DaVita Care (India) Private Limited, the Indian arm of DaVita Care Pte Ltd. 
  • 2020: Launched operations in Philippines by acquiring Royal Care Dialysis Center, Inc 
  • 2022: Launched operations in Uzbekistan after the award of PPP tender. 
  • 2024: Acquired a network of six clinics in Philippines pursuant to the acquisition of Renal Therapy Solutions Inc. 
  • 2025: Acquired and a chain of seven clinics (AIZ Hemodialysis Center Inc., Bioregen Hemo Center Inc., Carmona Dialysis System Inc., Infini Care Health Systems Inc., and Kolff Dialysis Inc.) 
  • 2025: Crossed 500 plus clinic globally.

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×